Penn Study Treats Alzheimer’s by Delivering Protein Across Blood-Brain Barrier

via Alzheimer’s Reading Room
University of Pennsylvania researchers have found a way of traversing the blood-brain barrier, as well as a similar physiological obstacle in the eye, the retinal-blood barrier

The body is structured to ensure that any invading organisms have a tough time reaching the brain, an organ obviously critical to survival. Known as the blood-brain barrier, cells that line the brain and spinal cord are tightly packed, making it difficult for anything besides very small molecules to cross from the bloodstream into the central nervous system. While beneficial, this blockade also stands in the way of delivering drugs intended to treat neurological disorders, such as Alzheimer’s.

In a new study published in the journal Molecular Therapy, University of Pennsylvania researchers have found a way of traversing the blood-brain barrier, as well as a similar physiological obstacle in the eye, the retinal-blood barrier. By pairing a receptor that targets neurons with a molecule that degrades the main component of Alzheimer’s plaques, the biologists were able to substantially dissolve these plaques in mice brains and human brain tissue, offering a potential mechanism for treating the debilitating disease, as well as other conditions that involve either the brain or the eyes.

The work was led by Henry Daniell, a professor in Penn’s School of Dental Medicine’s departments of biochemistry and pathology and director of translational research. The research team included Penn Dental Medicine’s Neha Kohli, Donevan R. Westerveld, Alexandra C. Ayache and Sich L. Chan. Co-authors at the University of Florida College of Medicine, including Amrisha Verma, Pollob Shil, Tuhina Prasad, Ping Zhu and Quihong Li, analyzed retinal tissues.

The researchers began their work by considering how they might breach the blood-brain barrier. Daniell hypothesized that a molecule might be permitted to cross if it was attached to a carrier that is able to pass over, as a sort of molecular crossing guard. The protein cholera toxin B, or CTB, a non-toxic carrier currently approved for use in humans by the Food and Drug Administration, is used in this study to traverse the blood-brain barrier.

They next identified a protein that could clear the plaques that are found in the brains of Alzheimer’s patients. These plaques, which are believed to cause the dementia associated with the disease, are made up of tangles of amyloid beta (A?), a protein that is found in soluble form in healthy individuals. Noting that myelin basic protein (MBP) has been shown to degrade A? chains, the team decided to couple it with CTB to see if MBP would be permitted to cross.

“These tangles of beta amyloid are known to be the problem in Alzheimer’s,” says Daniell. “So our idea was to chop the protein back to their normal size so they wouldn’t form these tangles.”

To test this idea, the Penn-led team first exposed healthy mice to the CTB-MBP compound by feeding them capsules of freeze-dried leaves that had been genetically engineered to express the fused proteins, a method developed and perfected by Daniell over many years as a means of orally administering various drugs and vaccines. Adding a green-fluorescent protein to the CTB carrier, the researchers tracked the “glow” to see where the mice took up the protein. They found the glowing protein in both the brain and retina.

“When we found the glowing protein in the brain and the retina we were quite thrilled,” said Daniell. “If the protein could cross the barrier in healthy mice, we thought it was likely that it could cross in Alzheimer’s patients brains, because their barrier is somewhat impaired.”

When CTB was not part of the fused protein, they did not see this expression, suggesting that their carrier protein, the crossing guard, was an essential part of delivering their protein of interest.

To then see what MBP would do once it got to the brain, Daniell and colleagues exposed the CTB-MBP protein to the brains of mice bred to have an Alzheimer’s disease. They used a stain that binds to the brain plaques and found that exposure to the CTB-MBP compound resulted in reductions of staining up to 60 percent, indicating that the plaques were dissolving.

Gaining confidence that their compound was appropriately targeting the plaques, the researchers worked with the National Institutes of Health to obtain brain tissue from people who died of Alzheimer’s and performed the same type of staining. Their results showed a 47 percent decrease in staining in the inferior parietal cortex, a portion of the brain found to play an important role in the development of Alzheimer’s-associated dementia.

As a final step, the researchers fed the CTB-MBP-containing capsules to 15-month-old mice, the equivalent of 80 or more human years, bred to develop Alzheimer’s disease. After three months of feeding, the mice had reductions in A? plaques of up to 70 percent in the hippocampus and up to 40 percent in the cortex, whereas mice fed capsules that contained lettuce leaves without CTB-MBP added and mice that were not fed any capsules did not have any reduction in evidence of brain plaques.

Because Alzheimer’s patients have also been found to have plaques in their eyes, the researchers examined the eyes of the mice fed the protein. They found that, indeed, the Alzheimer’s-mice did have retinal plaques, but those fed the CBP-MBP compound had undetectable A? plaques in their retinae.

See Also

“Really no one knows whether the memory problems that people who have Alzheimer’s disease are due to the dementia or problems with their eyes,” Daniell said. “Here we show it may be both, and that we can dissolve the plaques through an oral route.”

Read more . . .


The Latest on: Traversing the blood-brain barrier
  • Chevrolet Traverse
    on May 23, 2024 at 3:56 am

    Learn More. There are 2 recalls on this vehicle. Learn More. The second-generation Traverse three-row crossover delivers on room, comfort, refinement and connectivity. Not only is it competitive ...

  • Chevrolet Traverse
    on May 23, 2024 at 2:33 am

    RECALL ALERT: There are 3 recalls on this vehicle. Learn More. There are 3 recalls on this vehicle. Learn More. RECALL ALERT: There are 3 recalls on this vehicle. Learn More. There are 3 recalls ...

  • Indian voters dissect Modi's politics while traversing the country by train
    on May 20, 2024 at 9:24 pm

    ABOARD THE THIRUKKURAL EXPRESS, India — The 1,800-mile (2,900-kilometer) journey south from New Delhi to Kanyakumari is one of the longest train rides in India, passing through cities, villages ...

  • Indian voters dissect Modi's politics while traversing the country by train
    on May 20, 2024 at 5:01 pm

    The Associated Press rode one of the longest trains in India — 1,800 miles from New Delhi to Kanyakumari — to interview voters about an election that will be decided in June ABOARD THE ...

  • DSIP Peptide: Muscle, Pain, and Sleep
    on May 7, 2024 at 2:43 am

    Studies suggest that a naturally occurring neuropeptide, delta sleep-inducing peptide (DSIP), may traverse the blood-brain barrier. The DSIP peptide is being studied for its potential impact in ...

  • 2024 Chevrolet Traverse Squares Up with Turbo Power
    on May 1, 2024 at 5:00 pm

    The 2024 Chevrolet Traverse is arriving at dealers now, with a $38,995 starting price for the base, LS trim. The all-new crossover adds the off-road-centric Z71 package to the option list ...

  • Bathhouse Odyssey ‘Traversing the Mist’ Takes Top Prize at Paris’ NewImages
    on April 26, 2024 at 2:37 pm

    Director Chou Tung-Yen’s bathhouse cruising experience “Traversing the Mist,” a dreamlike odyssey awash in fear and flesh, took the top honors at Paris’ NewImages Festival on Friday ...

  • Breaching the barrier
    on April 22, 2024 at 9:20 am

    The blood-brain barrier has confounded the development ... One way of circumventing the 06-kDa size limit for biologics traversing the BBB is to design smaller versions of proteins.

  • Nanoparticles Deliver Drugs Directly Across the Blood-Brain Barrier
    on April 21, 2024 at 5:00 pm

    This process results in the formation of the protein/biomolecular corona. This composition enhances the nanocrystals’ ability to traverse the blood-brain barrier; our research shows that these gold ...

  • 2020 Chevrolet Traverse
    on April 10, 2024 at 12:05 am

    Need a vehicle with space for your family, but won't be seen in a minivan? Check out the Chevrolet Traverse. The three-row crossover was redesigned for 2018, becoming larger, lighter, and better ...

via  Bing News


The Latest on: Blood-brain barrier

via  Bing News

What's Your Reaction?
Don't Like it!
I Like it!
Scroll To Top